These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38368666)

  • 1. Expanding access to medication treatment for opioid use disorders: Findings from the Washington State hub and spoke effort.
    Stewart MT; Daily SM; Thomas CP; Panas L; Ritter G; Reif S
    Drug Alcohol Depend; 2024 Mar; 256():111125. PubMed ID: 38368666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.
    Reif S; Brolin MF; Stewart MT; Fuchs TJ; Speaker E; Mazel SB
    J Subst Abuse Treat; 2020 Jan; 108():33-39. PubMed ID: 31358328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.
    Rawson RA; Rieckmann T; Cousins S; McCann M; Pearce R
    Prev Med; 2019 Nov; 128():105785. PubMed ID: 31362002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization and disparities in medication treatment for opioid use disorder among patients with comorbid opioid use disorder and chronic pain during the COVID-19 pandemic.
    Perry A; Wheeler-Martin K; Hasin DS; Terlizzi K; Mannes ZL; Jent V; Townsend TN; Pamplin JR; Crystal S; Martins SS; Cerdá M; Krawczyk N
    Drug Alcohol Depend; 2023 Dec; 253():111023. PubMed ID: 37984034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C.
    Andraka-Christou B; Saloner B; Gordon AJ; Totaram R; Randall-Kosich O; Golan M; Stein BD
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):492-503. PubMed ID: 35772010
    [No Abstract]   [Full Text] [Related]  

  • 8. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
    Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
    Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
    Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
    J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
    Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
    Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
    JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV; Levin FR; Reilly MP; El-Bassel N
    J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings.
    Peterson L; Murugesan M; Nocon R; Hoang H; Bolton J; Laiteerapong N; Pollack H; Marsh J
    PLoS One; 2022; 17(10):e0276066. PubMed ID: 36256662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine Utilization and Prescribing Among New Jersey Medicaid Beneficiaries After Adoption of Initiatives Designed to Improve Treatment Access.
    Treitler P; Nowels M; Samples H; Crystal S
    JAMA Netw Open; 2023 May; 6(5):e2312030. PubMed ID: 37145594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dental care utilization in Massachusetts before and after initiation of medication for opioid use disorder: A cross-sectional study of a state all-payer claims database.
    Simon L; Choudhary A; Ticku S; Barrow J; Tobey M
    J Public Health Dent; 2022 Sep; 82(4):461-467. PubMed ID: 34816438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Primary Care in the Initiation of Opioid Use Disorder Treatment in Statewide Public and Private Insurance.
    Gertner AK; Rotter JS; Holly ME; Shea CM; Green SL; Domino ME
    J Addict Med; 2022 Mar-Apr 01; 16(2):183-191. PubMed ID: 33973922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of an office-based addiction treatment model for Medicaid enrollees: A mixed methods study.
    Treitler P; Enich M; Bowden C; Mahone A; Lloyd J; Crystal S
    J Subst Use Addict Treat; 2024 Jan; 156():209212. PubMed ID: 37935350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers.
    Mahone A; Enich M; Treitler P; Lloyd J; Crystal S
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):606-617. PubMed ID: 37506336
    [No Abstract]   [Full Text] [Related]  

  • 20. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.
    Hawkins EJ; Malte CA; Gordon AJ; Williams EC; Hagedorn HJ; Drexler K; Blanchard BE; Burden JL; Knoeppel J; Danner AN; Lott A; Liberto JG; Saxon AJ
    JAMA Netw Open; 2021 Dec; 4(12):e2137238. PubMed ID: 34870679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.